TLC590

Phase 3Small molecule

TTLC Biopharmaceuticals, Inc.

TLC590 is one of 17 small molecule programs targeting Post Operative Pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post Operative PainActive, not recruiting

Post Operative PainPhase 3

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Post Operative Pain

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

21 2

Duragesic

CCephalon

Approved

11 3

Ketalar

AAultman Health Foundation

Approved

9 4

ESP Block With Bupivacaine

YYale University

Approved

1 5

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Phase 3

2 6

EXPAREL

Pacira Pharmaceuticals, Inc

Phase 1

4 7

TLC590

TTLC Biopharmaceuticals, Inc.

Phase 3

1 8

Voltaren

Novartis

Preclinical

2 9

Oxycontin

PProtega

Preclinical

10 10

Toradol

JJavelin Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Surgical

NCT06574269

Clinical

Trials by Indication[1]

Postsurgical Pain Management3 trials

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Completed·TTaiwan Liposome Company·Phase 2·NCT03838133·150 enrolled

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

Completed·TTaiwan Liposome Company·Phase 1/2·NCT03591146·65 enrolled

Phase 2/3 Study of TLC590 for Postsurgical Pain Management

Not yet recruiting·TTaiwan Liposome Company·Phase 2/3·NCT05161637·415 enrolled

Surgical1 trial

A Study on TLC590 for Managing Postsurgical Pain

Recruiting·TTLC Biopharmaceuticals, Inc.·Phase 2·NCT06574269·120 enrolled

Post Operative Pain1 trial

A Phase 3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety and Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Active, not recruiting·TTLC Biopharmaceuticals, Inc.·Phase 3·NCT07222748·304 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TLC590. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TLC590 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TLC590. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TLC Biopharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTLC Biopharmaceuticals, Inc.

TLC590

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Postsurgical Pain Management3 trials

Surgical1 trial

Post Operative Pain1 trial

References

Drug Info

Quick Facts

Related News